Vaccination program in a resource-limited setting: A case study in the Philippines

Vaccine

Volumn 34, Issue 40, 2016, Pages 4814-4819

  Chootipongchaivat, Sarocha ^a   Chantarastapornchit, Varit ^a   Kulpeng, Wantanee ^a   Ceria, Joyce Anne ^b   Tolentino, Niña Isabelle ^b   Teerawattananon, Yot ^a  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b DEPARTMENT OF HEALTH   (Philippines)

Author keywords

HRH; Human resources for health; PCV; Philippines; Pneumococcal conjugate vaccine; Vaccination coverage

Indexed keywords

PNEUMOCOCCUS VACCINE; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

ANESTHESIST; ARTICLE; CASE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; GENERAL PRACTITIONER; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INTERVIEW; LOW INCOME COUNTRY; MARKOV CHAIN; MEDICAL DOCUMENTATION; MEDICAL PERSONNEL; MEDICAL SPECIALIST; MEDICAL TECHNOLOGIST; MIDWIFE; MONEY; NEUROLOGIST; NURSE; PEDIATRICIAN; PHARMACIST; PHILIPPINES; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RADIOLOGICAL TECHNOLOGIST; RADIOLOGIST; SOCIAL WORKER; ULTRASONOLOGIST; VACCINATION; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; PREVENTIVE HEALTH SERVICE;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; MODELS, ECONOMIC; PHILIPPINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 84995377332     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.08.014     Document Type: Article

References (25)

1. [1] Hongoro, C., McPake, B., How to bridge the gap in human resources for health. Lancet 364:9443 (2004), 1451–1456.
2. [2] Chen, L., Evans, T., Anand, S., Boufford, J.I., Brown, H., Chowdhury, M., et al. Human resources for health: overcoming the crisis. Lancet 364:9449 (2004), 1984–1990.
3. [3] Kollar, E., Buyx, A., Ethics and policy of medical brain drain: a review. Swiss Med Wkly, 143, 2013, w13845.
4. [4] Kinfu, Y., Dal Poz, M.R., Mercer, H., Evans, D.B., The health worker shortage in Africa: are enough physicians and nurses being trained?. Bull World Health Organ 87:3 (2009), 225–230.
5. [5] Hauck, K., Thomas, R., Smith, P.C., Departures from cost-effectiveness recommendations: the impact of health system constraints on priority setting. Health Syst Reform 2:1 (2016), 61–70.
6. [6] Biellik, R., Levin, C., Mugisha, E., LaMontagne, D.S., Bingham, A., Kaipilyawar, S., et al. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 27:44 (2009), 6203–6209.
7. [7] Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382:9888 (2013), 260–272.
8. [8] Bärnighausen, T., Bloom, D.E., Cafiero, E.T., O'Brien, J.C., (eds.) Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil. Seminars in immunology, 2013, Elsevier.
9. [9] Shepard, D.S., Suaya, J.A., Halstead, S.B., Nathan, M.B., Gubler, D.J., Mahoney, R.T., et al. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22:9 (2004), 1275–1280.
10. [10] Anand, S., Bärnighausen, T., Health workers and vaccination coverage in developing countries: an econometric analysis. Lancet 369:9569 (2007), 1277–1285.
11. [11] Haasis, M.A., Ceria, J.A., Kulpeng, W., Teerawattananon, Y., Alejandria, M., Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines. PLoS ONE, 10(7), 2015, e0131156.
12. [12] Kurowski, C., Mills, A., Estimating human resource requirements for scaling up priority health interventions in low income countries of Sub-Saharan Africa: a methodology based on service quantity, tasks and productivity. 2006, London School of Hygiene & Tropical Medicine, London.
13. [13] Kurowski, C., Wyss, K., Abdulla, S., Mills, A., Scaling up priority health interventions in Tanzania: the human resources challenge. Health Policy Plann 22:3 (2007), 113–127.
14. [14] PhilHealth, Performance report on PhilHealth use of CPGs for quality assurance and accreditation. HTA Forum, 4(1), 2006.
15. [15] Joint statement of the Philippine Society for Microbiology and Infectious Diseases PCoCP, Philippine Academy of Family Physicians, Philippine College of Radiology. Philippine clinical practice guidelines on the diagnosis, empiric management, and prevention of community-acquired pneumonia (CAP) in immunocompetent adults; 2010. < http://www.psmid.org.ph/clinical/cap_guidelines_2010.pdf>.
16. [16] World Health Organization. Midwifery education modules; 2008. < http://apps.who.int/iris/bitstream/10665/44145/6/9789241546669_6_eng.pdf>.
17. [17] World Health Organization, Managing newborn problems: a guide for doctors, nurses, and midwives. 2003, World Health Organization http://apps.who.int/iris/bitstream/10665/42753/1/9241546220.pdf.
18. [18] Philippine Statistics Authority. Projected populations by five-year age group and sex, by region and province, and by five-calendar years: 2000–2040, 2006.
19. [19] Canadian Agency for Drugs Technologies in Health, Guidelines for the economic evaluation of health technologies. 2006, CADTH, Canada.
20. [20] World Health Organization, WHO guide for standardization of economic evaluations of immunization programmes. 2008.
21. [21] Bhattarai, N., McMeekin, P., Price, C., Vale, L., Economic evaluations on centralisation of specialised healthcare services: a systematic review of methods. BMJ Open, 6(5), 2016, e011214.
22. [22] Vijgen, S., Opmeer, B.C., Mol, B., The methodological quality of economic evaluation studies in obstetrics and gynecology: a systematic review. Am J Perinatol 30:4 (2013), 253–260.
23. [23] Romualdez, A.G., dela Rosa, J.F., Fla vier, J.D.A., Quimbo, S.L.A., Hartigan-Go, K.Y., Lagrada, L.P., et al. The Philippines health system review. 2011, World Health Organization, Geneva.
24. [24] Finch, S., Philippines brain drain: fact or fiction?. Can Med Assoc J 185:12 (2013), E557–E558.
25. [25] Madhi, S.A., Adrian, P., Kuwanda, L., Jassat, W., Jones, S., Little, T., et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25:13 (2007), 2451–2457.